{"id":"W2523106824","doi":"10.1016/j.clml.2016.07.094","title":"Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nilotinib; Imatinib; Medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Internal medicine; Tyrosine kinase; Oncology; Dasatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001722875,0.0002155569,0.0008681915,0.0003094911,0.000228179,0.0006835705,0.0004498252,0.0004079712,0.001317913],"category_scores_gemma":[0.001778712,0.0001024463,0.0009996826,0.0003599775,0.0002418082,0.000831283,0.0004654788,0.001212163,0.0001283998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009246441,"about_ca_system_score_gemma":0.0009666382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001420908,"about_ca_topic_score_gemma":0.007083918,"domain_scores_codex":[0.9994417,0.0002123234,0.00004712265,0.00009121862,0.00007773243,0.0001299552],"domain_scores_gemma":[0.9990982,0.0002401869,0.0002461172,0.00005192157,0.00006903885,0.0002945561],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1533188,0.002921171,0.3417758,0.001019653,0.002021344,0.0002839995,0.0003055076,0.001382696,0.00250261,0.0006793428,0.008864642,0.4849245],"study_design_scores_gemma":[0.02190972,0.05403666,0.8974024,0.0004863774,0.00349721,0.0009458605,0.000509804,0.00166972,0.00109849,0.001109043,0.01727219,0.00006264537],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9733804,0.02099114,0.0002164675,0.0007873665,0.0002080404,0.0001149874,0.001236396,0.00001946628,0.003045663],"genre_scores_gemma":[0.9931527,0.002977499,0.0002319562,0.0007625713,0.0001421412,0.00005367219,0.001829768,0.000006202541,0.0008434634],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001722875,"threshold_uncertainty_score":0.009111524,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02560554150867721,"score_gpt":0.3167900096385131,"score_spread":0.2911844681298359,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}